苦参素对特发性肺纤维化患者血清基质金属蛋白酶9和转化生长因子β1的影响

Effect of oxymatrine on serum matrix metalloproteinase-9 and transforming growth factor-β1 in patients with idiopathic pulmonary fibrosis

目的观察并分析血清基质金属蛋白酶9（MMP-9）、转化生长因子β1TGF-β1）在特发性肺纤维化（IPF）病理过程中的作用，探讨苦参素对IPF的治疗价值。方法选取38例健康体检者为对照组，38例IPF患者为患者组。按随机数字表法将患者组分为常规治疗组（19例）和苦参素组（19例）。采用酶联免疫吸附试验法测定血清MMP-9、TGF-β1水平并比较。结果对照组与患者组治疗前血清MMP-9水平分别为（92．30±27．21）、（420．66±101．78）μg／L，两组比较差异有统计学意义（P〈0．05）。对照组与患者组治疗前血清TGF-β1水平分别为（67．36±13．03）、（217．82±43．90）μg／L，两组比较差异有统计学意义（P〈0．05）。常规治疗组与苦参素组治疗前血清MMP-9、TGF-β1水平比较差异无统计学意义（P〉0．05）；常规治疗组治疗后血清MMP-9水平显著下降，与治疗前比较差异有统计学意义[（138．91±35．09）μg／L比（428．21±102．75）μg／L]（P〈0．05），苦参素组治疗后血清MMP-9水平与治疗前比较差异无统计学意义（P〉0．05）；常规治疗组与苦参素组治疗后血清TGF-β1水平均显著下降，与治疗前比较差异有统计学意义[（145．42±30．78）μg／L比（200．34±58．96）μg/L；（102．37±26．04）μg／L比（219．78±63．20）μg／L]（P〈0．05）；常规治疗组与苦参素组治疗后血清MMP-9、TGF-β1水平比较差异有统计学意义（P〈0．05）。结论苦参素在有效降低IPF患者血清中较高水平的TGF-β1的同时，还可以维持MMP-9在含量较高的状态，对IPF有显著治疗作用。

[Abstract] Objective To study the effect ofoxymatrine on serum matrix metalloproteinase-9 （MMP-9） and transforming growth factor- β1 （TGF- β 1） in patients with idiopathic pulmonary fibrosis （IPF） and illuminate the mechanism and action. Methods Total 38 patients with IPF in the patient group were divided into the conventional treatment group and the oxymatrine group by random digits table method with 19 cases each. Meanwhile 38 healthy people were as the control group. Then serum MMP-9 and TGF- β1 levels were detected by enzyme-linked immunosorbent assay and compared. Results The serum MMP-9 level in the control group and the patient group was （92.30 ±27.21）, （420.66 ±101.78） μg/L, and there was significant difference （P 〈 0.05）. The serum TGF-β1 level in the control group and the patient group was （67.36 ± 13.03）, （217.82 ±43.90） μg/L, there was significant difference （P 〈0.05）. There was nosignificant difference in the serum MMP-9 and TGF-β1 level before treatment between the conventional treatment group and the oxymatrine group （P 〉 0.05 ）. There was significant difference in the serum MMP-9 level before and after treatment in the conventional treatment group [ （ 138.91 ± 35.09） μ g/L vs. （428.21 ± 102.75） μg/L] （P 〈 0.05）. There was no significant difference in the serum MMP-9 level before and after treatment in the oxymatrine group （P 〉 0.05 ）. There was significant difference in the serum TGF-β1 level before and after treatment in the conventional treatment group and the oxymatrine group [ （ 145.42 ± 30.78） μ g/L vs. （200.34 ± 58.96） μ g/L; （ 102.37 ± 26.04） μ g/L vs. （219.78 ±63.20）μ g/L] （P〈 0.05）. There was significant difference in the serum TGF-β1 level after treatment between the conventional treatment group and the oxymatrine group （P 〈 0.05 ）. Conclusion Oxymatrine can degrade IPF by reducing TGF- β1 and maintaining MMP-9 in the higher level.